1. Home
  2. FSLY vs CRNX Comparison

FSLY vs CRNX Comparison

Compare FSLY & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fastly Inc.

FSLY

Fastly Inc.

HOLD

Current Price

$33.99

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$39.98

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSLY
CRNX
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
FSLY
CRNX
Price
$33.99
$39.98
Analyst Decision
Hold
Strong Buy
Analyst Count
7
8
Target Price
$15.67
$76.63
AVG Volume (30 Days)
10.6M
1.1M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
27.19
N/A
EPS
N/A
N/A
Revenue
$624,018,000.00
$1,039,000.00
Revenue This Year
$16.43
$720.10
Revenue Next Year
$10.45
$184.67
P/E Ratio
N/A
N/A
Revenue Growth
14.78
N/A
52 Week Low
$5.13
$25.48
52 Week High
$34.22
$57.99

Technical Indicators

Market Signals
Indicator
FSLY
CRNX
Relative Strength Index (RSI) 69.83 57.82
Support Level $8.03 $39.35
Resistance Level N/A $45.32
Average True Range (ATR) 2.69 1.64
MACD 0.20 0.83
Stochastic Oscillator 92.95 94.39

Price Performance

Historical Comparison
FSLY
CRNX

About FSLY Fastly Inc.

Fastly Inc is a cloud computing company that provides an edge cloud platform designed to deliver, secure, and optimize digital experiences over the internet. The company operates a unified platform that combines content delivery, edge computing, and security capabilities. Its services include content delivery networks, web and API protection, distributed denial of service mitigation, and real-time data processing at the edge. Its platform enables customers to improve the performance, scalability, and security of applications and digital content, and also supports cloud-native architectures, AI-driven workloads, and programmable edge computing solutions.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: